Radiosynthesis of [11C]brofaromine a potential tracer for imaging monoamine oxidase A

Nuclear Medicine and Biology

Volumn 23, Issue 3, 1996, Pages 229-234

  Ametamey, S M ^a   Beer, H F ^a   Guenther, I ^a   Antonini, A ^a   Leenders, K L ^a   Waldmeier, P C ^b   Schubiger, P A ^a  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b CIBA GEIGY LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BROFAROMINE; CARBON; MONOAMINE OXIDASE INHIBITOR; AMINE OXIDASE (FLAVIN CONTAINING); BENZAMIDE DERIVATIVE; CLORGYLINE; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; IODINATED HYDROCARBON; ISOENZYME; METHYL IODIDE; MOCLOBEMIDE; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; ISOTOPE LABELING; MONKEY; POSITRON EMISSION TOMOGRAPHY; ANIMAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; FEMALE; MACACA; METABOLISM; METHODOLOGY; SCINTISCANNING; SYNTHESIS;

ANIMALS; BENZAMIDES; BRAIN; CARBON RADIOISOTOPES; CLORGYLINE; FEMALE; HYDROCARBONS, IODINATED; INDICATORS AND REAGENTS; ISOENZYMES; ISOTOPE LABELING; MACACA MULATTA; MOCLOBEMIDE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PIPERIDINES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029665294     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(95)02051-9     Document Type: Article

References (26)

1. i) receptor antagonist. IXth International Symposium on Radiopharmaceutical Chemistry, Abstracts, Paris., pp. 350-351.
2. Berger P. A. (1977). Antidepressant medications and the treatment of depression. In Psychopharmacology from Theory to Practice (Edited by Barchas J. D., Berger P.A., Ciaranelli R. D. and Elliott G. R.)-, pp. 174-207. Oxford University Press, New York.
3. Blaschko H. (1974). The natural history of amine oxidases. Rev. Physiol. Biochem. Pharmacol. 70, 81-148.
4. 11C]methyl iodide. Int. J. Appl. Radiat. Isot. 38, 601-604.
5. Elsworth J. D., Glover, V., Reynolds G. P., Sandlet M., Lees A. J., Phuapradit P., Shaw K. M., Stern G. M. and Kumar P. (1978). Deprenyl administration in man. A selective MAO-B inhibitor without the "cheese effect." Psychopharmacol. 57, 33-38.
6. 11C-labelled suicide inactivators and PET. Science. 235, 481-485.
7. Fuentes J. A. and Nef N. H. (1975). Selective monoamine oxidase inhibitor drugs as aids in evaluating the role of A and B enzymes. Neuropharmacol. 14, 819-825.
8. Fuentes J. A. and Nef N. H. (1977). Inhibition by pargyline of cardio-vascular amine oxidase activity. Biochem. Pharmacol. 26, 2107-2112.
9. Fuller R. W. (1968). Kinetic studies and in vivo effects of a new monoamine oxidase inhibitor N-(2(o-chlorphenoxy)-ethyl)-cyclopropylamine. Biochem. Pharmacol. 17, 2097-2106.
10. Fuller R. W. (1972). Selective inhibition of monoamine oxidase. Adv. Biochem. Psychopharmac. 5, 339-354.
11. 11C-labelling of the analgesic tramadol and its major metabolites by selective O- and N-methylation. Int. J. Appl. Radiat. Isot. 43, 1129-1137.
12. Garrick N. A., Scheinin M., Chang W. H., Linnoila M. and Murphy D. L. (1984). Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys. Biochem. Pharmacol. 33, 1423-1427.
13. Gorkin V. Z. and Tat'yaneko L. V. (1967). On the inhibition by harmine of oxidative deamination of biogenic amines. Life Sci. 6, 791-795.
14. Ishiwata K., Ido T., Yanai K., Kawashima K., Miura Y., Monma M., Watanuki S., Tahashi T. and Iwata R, (1985). Biodistribution of a positron-emitting suicide inactivators of monoamine oxidase, carbon-11 pargyline, in mice and a rabbit. J. Nucl. Med. 26, 630-636.
15. Johnston J. P. (1968), Some observation upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17, 1285-1297.
16. 11C]-1-deprenyl in mice: potential for measurement of functional monoamine oxidase activity in brain using positron emission tomography. Biochem. Pharmac. 34, 3207-3210.
17. Mantle T. J., Tipton K. F. and Garrett N. J. (1976). Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem. Pharmacol. 25, 2073-2077.
18. Murphy D. L. (1978). Substrate-selective monoamine oxidase inhibitor, tissue, species and functional differences. Biochem. Pharmacol. 27, 1889-1893.
19. Murphy D. L., Donnelly C. H., Richelson E. and Fuller R. W. (1978). N-substituted cyclopropylamines as inhibitors of MAO-A and -B forms, Biochem. Pharmacol 27, 176-179.
20. Ogren S. O., Ask A. J., Holm A. C., Florvall L., Lindbom L. O., Lundstrom J. and Ross J. B. (1981). Biochemical and pharmacological properties of a new selective and reversible monoamine oxidase inhibitor, FLA 336 (+). In Monoamine Oxidase Inhibitor - The State of the Art (Edited by Youdim M. B. H. and Paykel E. S.), pp. 631-637. Wiley, Chichester, UK.
21. Planz G., Quiring K. and Palm D. (1972). Rates of recovery of irreversible inhibited monoamine oxidase: a measure of enzyme protein turnover. Naunyn-Schmiedeberg's Arch. Pharmacol 273, 27-42.
22. 18F]fluoro-m-tyrosine, an enzyme-activated inhibitor of monoamine oxidase: Novel synthesis and in-vivo properties. In Nuclear Medicine. (Edited by Schmidt H. A. E. and Hoeffer R.), pp. 255-258. Schattauer, Stuttgart, New York.
23. Schiwy W., Heath W. R. and Delini-Stula A. (1989). Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients. J. Neural Transm. (Suppl.) 28, 33-44.
24. Waldmeier P. C., Feiner A. E. and Tripton K. F. (1983). The monoamine oxidase properties of CGP 11305 A. Eur. J. Pharmacol. 94, 73-83.
25. 3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide. Eur. J. Pharmacol. 180, 297-304.
26. Youdim M. B. H. and Oppenheim B. (1981). The effect of 1,2,3,4-tetrahydroβ-carbolines on monoamine metabolism in the human platelet and platelet aggregation. Neuroscience 6, 801-810.